Donate
|
Join/Renew
|
Store
|
Member Directory
|
My SNMMI
Search SNMMI.org
Search SNMMI Learning Center
Value Initiative
|
Physicians
|
Technologists
|
Scientists
|
Residents
|
Healthcare Provider
|
Patients
NEWS & PUBLICATIONS
News and Media
Newsletters
Journals
Books
MEMBERSHIP
Join/Renew
Benefits
Categories
Download a Member Application
Grants, Awards, and Scholarships
Access the Phantom Analysis Toolkit
Membership Directory
Chapters
Centers of Excellence
Councils
Member Spotlight
Women in Nuclear Medicine
SNMMI Fellow
SNMMI-TS Fellow
Council and Center Internships
EDUCATION
Learning Center
Webinars
MEETINGS & EVENTS
Calendar of Events
Webinars
2024 Annual Meeting
2024 Therapeutics Conference
2024 Mid-Winter Meeting
Nuclear Medicine & Molecular Imaging Week
ADVOCACY
Coding & Reimbursement
Legislative Efforts
Government Relations News
Radiopharmaceutical Supply News
USP 825
Technologist State Issues
Position Statements
FDA PET Drug Manufacturing Q&A
EVIDENCE & QUALITY
Clinical Guidelines and AUC
Quality
Quality and Patient Safety
Dose Optimization
About Quality & Practice
Dosimetry
RESEARCH
Clinical Trials Network
Radiopharmaceutical Therapy Central
Radiopharmaceutical Therapy Centers of Excellence
Preclinical Imaging
Nuclear Medicine Clinical Trial Group, LLC
Research: Learn More
ABOUT SNMMI
Strategic Plan
Bylaws & Procedures
Governance - SNMMI
Governance - SNMMI-TS
History
Grants, Awards, and Scholarships
Career Center
About Nuclear Medicine & Molecular Imaging
International Collaboration
Outreach
Support SNMMI
Contact Us
HOME
>
SEARCH
>
SEARCH RESULTS
Refine by Audience:
Physicians
(127)
Technologists
(127)
Scientists
(127)
Media
(126)
Healthcare Provider
(123)
Your search for
pilot research
returned 127 results.
Selected filters:
Patients
International
Displaying 31 to 40 of 127 records
Sort by:
Relevancy
Date Added
Page:
<< Prev
1
…
2
…
3
…
4
…
5
…
6
…
7
…
Next >>
Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients
– Sep 27, 2023
A new imaging agent, Ga-68-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in JNM.
First Three Facilities Accredited in SNMMI/IAC Radiopharmaceutical Therapy Accreditation Program
– Sep 25, 2023
SNMMI and the Intersocietal Accreditation Commission are pleased to announce the first three facilities to be awarded the new Radiopharmaceutical Therapy Accreditation.
Nuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting
– Sep 18, 2023
A new 225Ac-DOTA-based pre-targeted radioimmunotherapy system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects, according to research published in JNM.
JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy
– Sep 1, 2023
SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with Lu-177 PSMA radionuclide therapy.
PSMA PET/CT Waives the Need for Pre-Imaging Biopsy in Elderly Patients
– Aug 14, 2023
In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy, according to new research published in JNM.
Clinical Trials Network
– Aug 3, 2023
The SNMMI Clinical Trials Network provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Increased standardization in trials leads to better data that then results in expanded utilization of radiopharmaceuticals.
SNMMI Keeps Eye on the Patient at 2023 Annual Meeting
– Jun 28, 2023
SNMMI hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed Eye on the Patient, held in Chicago, Illinois.
Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease
– Jun 27, 2023
A novel PET perfusion radiotracer, F-18 flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to Tc-99m SPECT myocardial perfusion imaging, according to research presented at the 2023 SNMMI Annual Meeting.
Personalized Dosing in Prostate Cancer Treatment Improves Patient Outcomes
– Jun 27, 2023
By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.
Novel Theranostic Agent Targets Multiple Cancer Types
– Jun 27, 2023
A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach.
Displaying 31 to 40 of 127 records
Page:
<< Prev
1
…
2
…
3
…
4
…
5
…
6
…
7
…
Next >>
Didn't find what you were looking for? Conduct a new search.